ADA Conference Highlights Obesity Drug Competition and Clinical Practice Gaps
The American Diabetes Association's annual conference featured industry discussions on the competitive landscape for GLP-1 obesity medications and identified clinical blind spots in diabetes care delivery. The conference addressed how pharmaceutical competition is shaping market access and pricing dynamics for widely-used medications including semaglutide and tirzepatide. For Medicaid managed care organizations, these developments directly affect formulary strategy, prior authorization protocols, and budget forecasting for one of the fastest-growing drug spending categories.
Medicaid MCOs face escalating costs and utilization management challenges for GLP-1 medications, which represent significant budget pressure while state coverage policies and clinical criteria continue to evolve rapidly.
Managed Care · Pharmacy
You might also like